Weight Loss
Weight loss, fat loss and appetite control peptides: incretin, fragment and mitochondrial compounds, grouped by the receptors they act on.
8 products
Weight loss peptides and how they differ
This range covers the incretin receptor agonists that dominate the current literature: the GLP-1 receptor agonist semaglutide, the dual GIP and GLP-1 agonist tirzepatide and the triple agonist retatrutide. Alongside them sit the growth hormone fragment AOD-9604 and its parent fragment 176-191, the NNMT inhibitor 5-Amino-1MQ and the mitochondrial-derived peptide MOTS-c.
Each compound page sets out which receptors the molecule acts at and how it differs from its nearest relatives, with references to the primary literature, so you can pick the right compound for a comparison.
Fat loss, appetite and metabolism
The incretins work on appetite signalling and gastric emptying. AOD-9604 and the 176-191 fragment are growth hormone fragments studied for lipolysis rather than for growth. 5-Amino-1MQ and MOTS-c sit on the metabolic side: NNMT inhibition and mitochondrial peptide signalling respectively.
That split is why the range is listed together. If you want the appetite route, look at the incretins. If you want the fat oxidation or metabolic route, look at the fragments, 5-Amino-1MQ and MOTS-c.
Comparing strengths and cost per mg
Most compounds in this range are offered in several vial strengths. The card shows the lowest price; the product page lists every strength and its cost per mg. Larger vials generally have a lower cost per mg and suit anyone drawing repeated aliquots from a single preparation.







